Visual Abstract (IMAGE)
Caption
Compared to breast cancer patients with a negative test result, those with a BRCA1/2 variant may not receive guideline-concordant treatment.
Credit
University of Michigan Rogel Cancer Center
Usage Restrictions
for use in stories about this research
License
Licensed content